How Treatment Improves Polycythemia Vera Life Expectancy

Improved treatments have increased survival

Polycythemia vera is a medical condition that causes the body to make too many red blood cells. It is classified as a type of cancer. The excess red blood cells can cause dangerous complications such as blood clots, but the red blood cells do not invade healthy tissue. Polycythemia vera can progress to myelofibrosis or acute myeloid leukemia, which are aggressive types of cancer.

This condition can be treated with medical interventions and medication to reduce the effects of complications and improve life expectancy. Since there is no cure, disease surveillance and treatment have to be continued long term.

This article will discuss the life expectancy for polycythemia vera with or without treatment, and what treatments may be offered.

Polycythema treatment can involve phlebotomy

Pavel Peskov / EyeEm / Getty Images

What Is Polycythemia Vera? 

Polycythemia vera is caused by an abnormality in the red blood cell production that begins in the bone marrow. Secondary polycythemia is a similar condition that occurs due to an underlying disease. Both conditions cause the body to make too many red blood cells, but secondary polycythemia is not considered a type of cancer.

Polycythemia vera is defined by:

  • Hemoglobin (the oxygen-carrying molecule in red blood cells) is higher than 16.5 grams/deciliter (g/dl) for males (normal is 13.2–16.6 g/dL) or higher than 16.0 g/dL for females (normal is 11.6–15 grams/dL).
  • Hematocrit (the percentage of blood that is red blood cells) is higher than 49% for males (normal is 38.3%–48.6%) or higher than 48% for females (normal is 35.5%–44.9%).
  • Mutation in the gene that codes for the Janus kinas 2 (JAK2) protein may be present.
  • Characteristic changes are seen in the red blood cell precursors (substances from which red blood cells form) in the bone marrow.
  • Erythropoietin, the hormone that stimulates red blood cell production, may be elevated.

Secondary polycythemia can occur due to medical conditions that cause the body to make too many red blood cells. These include heart disease, lung disease, sleep apnea, and some cancers. 

Polycythemia Vera Life Expectancy

Polycythemia vera can lower a person’s life expectancy due to complications, including blood clots that can affect the heart, brain, lungs, or other organs. These effects may cause lasting disability and can be fatal. Survival rates have been increasing due to improved treatments.

Secondary polycythemia is associated with an increased risk of death as well.

Without Treatment 

If you are not treated for polycythemia vera, it can lead to death within months or years, but you can survive for longer. The exact survival with polycythemia vera without treatment is not known. A person may survive for many years if complications do not occur. Sometimes, even with specific treatment to manage complications, the complications can be fatal.

It is not possible to predict whether a person who is diagnosed with polycythemia vera will develop complications, when they may occur, or the severity and effects of the complications. 

With Treatment 

Treatment prolongs survival because it can help prevent serious complications of the condition. Interventions can help prevent complications from happening and may help reduce the severity and frequency of complications. Complications of polycythemia require their own treatment.

With treatment, the median survival rate is approximately 15 years after diagnosis, and for patients aged 40 or younger, median survival is 37 years after diagnosis. 

After a Polycythemia Vera Diagnosis 

If you are diagnosed with polycythemia vera or secondary polycythemia, you may need to start treatment. The treatment will depend on your red blood cell values, your symptoms, your risk factors for complications, and any complications that you have already experienced. 

Treatments include:

  • Phlebotomy is used to remove blood from the body Like a blood donation, a line is inserted into a vein and blood is collected in a blood collection bag. This procedure may need to be repeated at regular intervals or when the red blood cell count increases.
  • Aspirin is used to prevent blood clots.
  • Medications include Droxia (hydroxyurea), Multiferon (interferon alpha), and Jakafi (ruxolitinib phosphate), a JAK inhibitor. used to inhibit the production of red blood cells.

If you have secondary polycythemia, the treatment is focused on the management of the causative primary disease. In some instances, phlebotomy is necessary for the treatment of secondary polycythemia as well.

Continuing With Treatment 

Treatment needs for polycythemia vera may change over time. You will need to have your red blood cell count, hemoglobin, and hematocrit measured periodically to determine which treatments you should continue. 

Summary 

Polycythemia vera and secondary polycythemia are conditions in which the body makes too many red blood cells. These conditions need to be treated because they can cause serious complications and may affect survival. With treatment, life expenctancy is substantially improved.

Polycythemia vera is treated with phlebotomy (removal of blood), aspirin to prevent blood clots, and medications to reduce red blood cell production. Secondary polycythemia requires management of the underlying condition and sometimes phlebotomy.

A Word From Verywell

Living with polycythemia vera or secondary polycythemia means that you have to be attentive to your health and your medical care. Treatment and surveillance of the effects of your disease must be consistent and lifelong. While polycythemia can present challenges, treatment will help improve your quality of life and life expectancy.

Frequently Asked Questions

  • How fast does polycythemia vera affect the body over time?

    Polycythemia vera progresses slowly over the course of many years. It can cause dizziness, fatigue, headaches, and itchy skin. It may also cause bleeding, an enlarged spleen, and joint swelling.

    Over time, it can cause damage to the joint and it can cause harmful blood clots that may cause a deep vein thrombosis (a blood clot in a large vein), heart attack (a blood clot blocks flow to the heart muscle), stroke (a blood clot blocks blood flow in the brain), or pulmonary embolus (a blood clot in the lungs).

    The risk for deep vein thrombosis is highest in people over 60 or those who have had a clotting problem in the past. Risks are also higher for people who have other risk factors for cardiovascular disease (smoking, high cholesterol, or high blood pressure, and diabetes mellitus, a condition in which the pancreas doesn't produce enough insulin).

  • Why is polycythemia vera considered cancer?

    This condition is considered a type of cancer because it is characterized by excess production of cells, which is a feature of cancer. 

  • Can people with polycythemia vera lead a healthy life?

    If the condition is mild or if treatment is effective, a person can lead a healthy life with polycythemia vera. Even of your condition is mild, it’s important to get medical attention for new or worsening symptoms and to have medical surveillance for signs of complications.

Was this page helpful?
7 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Leukemia and Lymphoma Society. Polycythemia vera.

  2. Iurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: From diagnosis to therapy. Int J Mol Sci. 2020;21(16):5805. doi:10.3390/ijms21165805

  3. Guo L, Chughtai AR, Jiang H, et. al. Relationship between polycythemia and in-hospital mortality in chronic obstructive pulmonary disease patients with low-risk pulmonary embolism. J Thorac Dis. 2016;8(11):3119-3131. doi:10.21037/jtd.2016.11.31

  4. Gerds AT, Dao KH. Polycythemia vera management and challenges in the community health setting. Oncology. 2017;92(4):179-189. doi:10.1159/000454953

  5. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599-1613. doi:10.1002/ajh.26008

  6. Arya Y, Syal A, Gupta M, Gaba S. Advances in the treatment of polycythemia vera: Trends in disease management. Cureus. 2021;13(3):e14193. doi:10.7759/cureus.14193

  7. National Center for Advancing Translational Sciences. Polycythemia vera,